NA
ANIK icon

Navellier & Associates’s Anika Therapeutics ANIK Stock Holding History

Navellier & Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,423
Closed -$314K – 279
2016
Q4 		$314K Sell
6,423
-156
-2% -$7.21K 0.05% 219
2016
Q3 		$315K Buy
+6,579
New +$325K 0.05% 202
2014
Q3 		– Sell
-13,364
Closed -$619K – 325
2014
Q2 		$619K Buy
+13,364
New +$594K 0.03% 158

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Navellier & Associates's ANIK Position: Q1 2017 in Review

Navellier & Associates sold out of Anika Therapeutics (ANIK) in Q1 2017, closing a stake of 6,423 shares — an estimated $314K sold.

Navellier & Associates first reported a position in ANIK in Q2 2014 and held it in 3 quarters. The position peaked at $619K in Q2 2014. 156 funds tracked by Wall St. Rank hold ANIK as of Q1 2017.

  • Navellier & Associates reported no remaining Anika Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Navellier & Associates sold 6,423 Anika Therapeutics shares in Q1 2017, an estimated $314K.
  • Navellier & Associates first reported a position in Anika Therapeutics in Q2 2014 and held it in 3 quarters.
  • Navellier & Associates's Anika Therapeutics position peaked at $619K in Q2 2014.
  • 156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2017.

Based on Navellier & Associates's 13F filing for Q1 2017, filed 21 Apr 2017.